Skip to main content
TheraSphere Y-90 Glass Microsphere glowing against blue background.

TheraSphere™ Y-90 Glass Microspheres

Hit tumors* hard with TheraSphere

TheraSphere is a targeted, FDA-approved radioembolization therapy. It consists of millions of glass microspheres containing radioactive Yttrium-90 (Y-90). TheraSphere allows for personalized and flexible dosing by offering both standard and custom vial options.

The evidence is in. 100% tumor response.¹

TheraSphere is the only Y-90 treatment assessed in over 100 clinical studies globally, confirming its effectiveness and impact on liver tumor response.

truck in motion icon.

Get started with TheraSphere

Order TheraSphere using TheraSphere Now, a cloud-based website that facilitates personalized treatment order submission, tracking and order management.


Find coding and economic resources for health care practitioners and their partners.


  1. LEGACY: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819. Percentage shown reflects patients who were eligible for tumor response assessment.
  2. Pasciak, A. S., Abiola, G., Liddell, R. P., Crookston, N., Besharati, S., Donahue, D., Thompson, R. E., Frey, E., Anders, R. A., Dreher, M. R., & Weiss, C. R. (2019). The number of microspheres in Y-90 radioembolization directly affects normal tissue radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 816–827.

*Refers to HCC or associated tumors .